Ticker brief

ORKA ORUKA THERAPEUTICS INC

Consumer, Non-cyclical · Biotechnology

last close
$91.14
1 day
-5.6%
14 days
-17.9%
mkt cap
$5.1B
signals 14d
6
authors 14d
6
crowd 14d
+0.3σ
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d95%IV/HV 1.58× (as of 2026-08-26)
Skew — 25Δ RR 30d-0.02025Δ call IV − put IV
Net dealer OI (NDOI)+0.23 elevated5-session Δ +0.06 (as of 2026-07-01)
OI alarmquietlast alarm 2026-04-30 (z=3.1)
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-27 · now +0.20 (−1 bearish … +1 bullish)
Who spoke6
authorgradetrader scoresignalsmean sent
@AponiaAnalyticsB+4.911-0.15
@SteveDJacobsC-1.221+0.15
@bioinvestor24A-0.451+0.55
@EmmanuelInvestC-1.111+0.10
@Biotech2k1A+1.021+0.15
@PrismMarketViewC·1+0.20
Recent signals6of 6 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-08-27@PrismMarketView+0.20Presents four biotech companies advancing approved or investigational psoriasis treatments.-5.6%
2026-08-25@Biotech2k1+0.15Names several companies as examples, but the parent context is missing.-10.5%
2026-08-24@EmmanuelInvest+0.10Reports ORKA appointing an experienced chief commercial officer effective August 24.-11.0%
2026-08-23@bioinvestor24+0.55Calls the three Paragon spinouts the best immunology companies and cites their gains.-15.6%
2026-08-16@SteveDJacobs+0.15Publishes a Qullamaggie technical scan; output is capped at the first six stocks.-17.9%
2026-08-15@AponiaAnalytics-0.15Insider exercised options and sold the resulting shares under a prearranged plan-17.9%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.